ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2026
Modulation of the AMPK/TFEB Axis by Ezetimibe Attenuates Neuroinflammatory, Oxidative Stress, and Neurotransmitter Dysregulation in Naloxone-precipitated Tramadol Withdrawal in Mice.
Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tramadol withdrawal is associated with neuroinflammation, oxidative stress, and neurotransmitter imbalance, yet effective therapeutic strategies remain limited. Activation of the AMPK–TFEB (AMP-activated protein kinase-transcription factor EB) signaling axis enhances autophagy and cellular homeostasis and may mitigate withdrawal-associated neurotoxicity. To investigate whether ezetimibe attenuates naloxone-precipitated tramadol withdrawal in mice through modulation of the AMPK/TFEB pathway. Swiss albino mice received chronic tramadol exposure followed by naloxone to induce withdrawal. Ezetimibe (5 and 10 mg/kg, p.o.) was administered with or without the TFEB inhibitor eltrombopag. Behavioral outcomes (withdrawal severity score, jumping frequency, hyperalgesia), oxidative stress and inflammatory markers, neurotransmitter levels, and molecular docking interactions with TFEB were evaluated. Ezetimibe significantly reduced withdrawal severity, jumping frequency, hyperalgesia, lipid peroxidation, glutamate levels, and pro-inflammatory cytokines, while restoring antioxidant status, dopamine, and serotonin. Co-administration of eltrombopag attenuated these effects. Docking analysis revealed a stable interaction between ezetimibe and TFEB. Ezetimibe ameliorates tramadol-withdrawal-induced neurobehavioral and molecular alterations, most likely via AMPK-mediated activation of TFEB and enhancement of autophagy, highlighting its therapeutic potential in opioid withdrawal.
Indexed as
Identifiers
41944914What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.